Bibliography
- CHI L, ROGERS KL, UPRICHARD ACG, GALLAGHER KP: The therapeutic potential of novel anticoagulants. Exp. Opin. Invest. Drugs (1997) 6(10:1501–1622.
- •Thorough overview of novel anticoagulants.
- BATES SM, WEITZ JI: The new heparins. Coron. Artery Dis. (1998) 9:65–74.
- SINHA U: Synthetic inhibitors of coagulation Factor Xa. Exp. Opin. Invest. Drugs (1999) 8(5):567–573.
- EWING WR, PAULS HW, SPADA AP: Progress in the design of inhibitors of coagulation Factor Xa. Drugs Fut. (1999) 24(7):771–787.
- SANDERSON PEJ: Small, noncovalent serine protease inhibitors. Med. Res. Rev. (1999) 19(2):179–197.
- HAUPTMANN J, STURZEBECHER J: Synthetic inhibitors of thrombin and Factor Xa: From bench to bedside. Thromb. Res. (1999) 93:203–241.
- WALENGA JM, JESKE WP, HOPPENSTEADT D, KAISER B: Factor Xa inhibitors: Today and beyond. Curr. Opin. Cardiov. Pulmon. Renal Inves. Drugs (1999) 1(0:13–27.
- VACCA JP: Thrombosis and coagulation. Ann. Reports Med. Chem. (1998) 33:81–90.
- AL-ODEIDI F, OSTREM JA: Factor Xa inhibitors by classical and combinatorial chemistry. Drug Discovery Today (1998) 3(5):223–231.
- WALENGA JM, JESKE WP, BARA L, SAMAMA MM, FAREEDJ: Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb. Res. (1997) 86:1–36.
- ••Rationale for the development of synthetic heparinpentasaccharides.
- BONEU B, NECCIARI J, CARIOU R et al: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/0RG31540) with high affinity to antithrombin III in man. Thromb. HaemosL (1995) 74 (6) :1468–1473.
- ••Phase I study with 5R90107A/0RG31540.
- VUILLEMENOT A, SCHIELE F, MENEVEAU N etal.: Efficacy of a synthetic pentasaccharide, a pure Factor Xa inhibitor, as an antithrombotic agent - A pilot study in the setting of coronary angioplasty. Thromb. HaemosL (1999) 81:214–220.
- ••Phase II study with 5R90107A/0RG31540.
- JAFARY F: SR90107A/0RG31540, a new synthetic pentasaccharide, as an adjunct to fibrinolysis in ST-elevation acute myocardial infarction: the PENTALYSE Study. American College of Cardiology Scientific Session 2000. Late-Breaking Clinical Trial Results - Session II. Anaheim, CA, USA (2000):May.
- •This study was presented at the American College of Cardiology Meeting in Anaheim, California on March 15, 2000.
- MURAYAMA N, TANAKA M, KUNITADA S et al.: Tolerability, pharmacokinetics and pharmacody-namics of DX-9065a, a new synthetic potent anticoagu-lant and specific Factor Xa inhibitor, in healthy male volunteers. Clin. Pharmacol Ther. (1999) 66:258–264.
- ••Phase I study with DX-9065a.
- MURAYAMA N, TANAKA S, KIKUCHI T, NAKAOKA M, SUDO K: Radioimmunoassay method of DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma. J. Pharm. Biomed. Anal. (1996) 14:1435–1445.
- ••Assay development for measuring DX-9065a in plasma withreference to oral administration in one healthy volunteer.
- YOKOYAMA T, KELLY AB, MARZEC UM, HANSON SR, KUNITADA S, HARKER LA: Antithrombotic effects of orally active synthetic antagonist of activated Factor X in nonhuman primates. Circulation (1995) 92:485–491.
- ••Effect of intravenously and orally administered DX-9065a ina baboon model of arteriovenous shunt thrombosis.